Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolpropamine is a first-generation antihistamine of the alkylamine class with anticholinergic properties, primarily used as an antipruritic and topical antihistaminic. It acts as an H1 receptor antagonist, blocking the action of histamine at H1 receptors to reduce allergic symptoms such as itching and inflammation. Tolpropamine is noted for its rapid onset and minimal sedative effects compared to older antihistamines. Its mechanism involves interfering with histamine-induced signaling pathways, stabilizing mast cells, reducing pro-inflammatory cytokine expression via NF-κB inhibition, and decreasing further histamine release. It is mainly indicated for conditions like allergic rhinitis, urticaria (hives), and other dermatological allergies[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tolpropamine.